GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883409/0/en/GLUCOTRACK-S-EPIDURAL-GLUCOSE-MONITORING-SENSOR-DEMONSTRATES-SUCCESSFUL-30-DAY-SAFETY-PERFORMANCE-IN-LONG-TERM-PRECLINICAL-STUDY.html

Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy

Rutherford, NJ, May 16, 2024 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq:GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that its implantable continuous glucose monitor has successfully completed 30 days of a 60-day long-term preclinical study on measuring glucose in the epidural space.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.